Table 1.
Participants baseline characteristics, according to the presence of testosterone deficiency
| Total (n = 245) |
Testosterone deficiency (n = 72) |
Without testosterone deficiency (n = 173) |
p value | |
|---|---|---|---|---|
| Age [years, median (IQR)] | 48.0 (15.0) | 51.5 (11.8) | 48.0 (7.3) | <0.001a |
| Duration of HIV infection [years, median (IQR)] | 8.0 (6.0) | 6.0 (8.0) | 8.0 (6.0) | 0.567a |
| HIV stage [n (%)]d | ||||
| A | 122 (52.1) | 31 (44.9) | 91 (55.2) | 0.157b |
| B | 12 (5.1) | 6 (8.7) | 6 (3.6) | |
| C | 100 (42.7) | 32 (46.4) | 68 (41.2) | |
| cART [years, median (IQR)] | 6.0 (7.0) | 4.5 (8.8) | 7.0 (6.0) | 0.447a |
| NRTI [n (%)] | 213 (86.9) | 67 (31.5) | 146 (84.4) | 0.067c |
| NNRTI [n (%)] | 104 (42.4) | 33 (45.8) | 71 (41.0) | 0.489b |
| PI [n (%)] | 119 (48.6) | 33 (45.8) | 86 (49.7) | 0.580b |
| FI [n (%)] | 1 (0.4) | 0 | 1 (0.6) | 0.999c |
| II [n (%)] | 16 (6.5) | 6 (8.3) | 10 (5.8) | 0.570c |
| Viral load (<50) [n (%)] | 131 (82.4) | 33 (76.7) | 98 (84.5) | 0.255b |
| CD4 count [cells/mm3, median (IQR)] | 477.0 (327.3) | 501.0 (351.5) | 526.5 (286.8) | 0.157a |
| HIV risk factor [n (%)] | ||||
| Injecting drug user | 55 (23.7) | 18 (26.5) | 37 (22.6) | 0.561b |
| Heterosexual contact | 118 (50.9) | 37 (54.4) | 81 (49.4) | |
| Homosexual contact | 50 (21.6) | 11 (16.2) | 39 (23.8) | |
| Others | 9 (3.9) | 2 (2.9) | 7 (4.3) | |
cART combined antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, FI fusion inhibitor, II integrase inhibitor
aMann-Whitney U test; bChi-square test, cFisher test; dInformation only available for 234 patients